News
- Homepage
- >
- News
Latest news
-
21 October 2024SERB Pharmaceuticals expands leading emergency care portfolio with acquisition of Aurlumyn™ (iloprost IV) for severe frostbitePhiladelphia, 21 October 2024: SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today the acquisition of Aurlumyn™ (iloprost IV), the only FDA approved treatment option for severe frostbite in the US, from CiVi Biopharma. Aurlumyn™ will be made available this coming winter season. Arthur Pignot, Chief Strategy Officer at SERB, said: “Aurlumyn™ is set to […]
-
02 August 2024FDA has accepted a BLA for bentracimab, the first and only ticagrelor reversal agent, for filing and priority reviewPleasanton, CA and Philadelphia, PA – 2 August 2024: SFJ Pharmaceuticals, (SFJ), Sponsor of the bentracimab Biologics License Application (BLA), and SERB Pharmaceuticals (SERB), who acquired exclusive US rights to bentracimab from SFJ and will commercialize bentracimab in the United States, announced today that the US Food and Drug Administration (FDA) has accepted the bentracimab […]
-
31 July 2024SERB Pharmaceuticals strengthens leadership in medical countermeasures with the global acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit for $75 millionPhiladelphia, PA, 31 July 2024: SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today the acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions Inc. (NYSE: EBS) for an up-front payment of approximately $75 million. In addition, SERB will pay Emergent a $5 million payment upon first achievement of a milestone relating to […]
News archive
Date
Title